Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab with Chemotherapy in Advanced NSCLC (Lung-TRIO)
NCT01038037Phase 2
Key facts
- Status
- Terminated
- Start
- Jan 2010
- Primary completion
- Jun 2013
- Countries
- 1
- Sponsor
- Vejle Hospital
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Drugs
- panitumumab
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, randomised, open-label trial of panitumumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Vejle Hospital. Primary endpoint: Response Rate up to 3 years. Started Jan 2010; status: terminated.
02
Design
2 arms- Study design
- RandomizedOpen-label
Panitumumab + Chemotherapy
Panitumumab added to standard Carboplatin and Vinorelbine chemotherapy
Chemotherapy Alone
Standard Carboplatin and Vinorelbine chemotherapy
03
Who it enrols
Patients with metastatic (stage IV) NSCLC who are KRAS, BRAF, and PI3K wild type.
04
Endpoints
Primary
Response Rate
Secondary
Progression Free Survival
Overall Survival
Beyond the preview
Go deeper on NCT01038037.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01038037.